Last $33.21 USD
Change Today +2.80 / 9.21%
Volume 301.9K
EPZM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Open
$30.84
Previous Close
$30.41
Day High
$33.33
Day Low
$30.52
52 Week High
10/1/13 - $42.71
52 Week Low
11/14/13 - $18.10
Market Cap
1.1B
Average Volume 10 Days
208.4K
EPS TTM
$-0.29
Shares Outstanding
33.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors. The company has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

74 Employees
Last Reported Date: 02/28/14
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, Secretary and Direct...
Total Annual Compensation: $564.7K
President, Chief Financial Officer, Principal...
Total Annual Compensation: $513.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $487.5K
Chief Medical Officer
Total Annual Compensation: $463.5K
Compensation as of Fiscal Year 2013.

epizyme inc (EPZM) Key Developments

Epizyme Mulls Acquisitions

Epizyme, Inc. (NasdaqGS:EPZM), which has filed for a shelf registration in the amount of $200 million, is looking for acquisitions. The company stated, “We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the acquisition of companies or businesses, repayment and refinancing of debt, if any, working capital and capital expenditures.”

Epizyme, Inc. Announces Board Changes

Epizyme, Inc. in its AGM held on June 9, 2014, elected Andrew R. Allen, M.D., Ph.D. as a class I director, for a three-year term ending at the annual meeting of stockholders to be held in 2017. Thomas O. Daniel, M.D. and Kazumi Shiosaki, Ph.D. did not stand for re-election at the Annual Meeting of Stockholders. Dr. Shiosaki delivered a written resignation to the company on June 9, 2014 confirming that she no longer serves as a director.

Epizyme, Inc. Announces Presentation on Pre-Clinical Models and Early Clinical Observations of EZH2 Inhibitor EPZ-6438

Epizyme, Inc. announced that an abstract on EPZ-6438 has been accepted for oral presentation at the American Society of Hematology (ASH) Meeting on Lymphoma Biology, to be held August 10-13 in Colorado Springs, Colorado. The presentation will include findings characterizing the activity of EPZ-6438, a small molecule inhibitor of EZH2, in pre-clinical models of non-Hodgkin lymphoma (NHL), both as a single agent and in combination with NHL standards of care. The presentation will also highlight the early clinical experience from an ongoing Phase 1 study of EPZ-6438 (E7438) in patients with advanced malignancies, including NHL. Activity of the EZH2 inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-clinical Models and Early Clinical Observations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $33.21 USD +2.80

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies
 

Industry Analysis

EPZM

Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.